Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
NASDAQ Composite
Standard & Poors 500
My Portfolio
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
398.08
-23.91 (-5.67%)
Delayed Quote
Updated: 4:00 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Kaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Today 13:45 EST
From
Kaplan Fox & Kilsheimer, LLP
Via
GlobeNewswire
Kaplan Fox Announces an Investigation Into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Possible Securities Law Violations
November 17, 2026
NEW YORK, NY - November 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:...
Via
NewMediaWire
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations
November 16, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation of Potential Securities Law Violations
November 16, 2026
From
Kaplan Fox & Kilsheimer, LLP
Via
GlobeNewswire
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations - Investors Encouraged to Contact the Firm
November 13, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations
November 13, 2026
From
Kaplan Fox & Kilsheimer, LLP
Via
GlobeNewswire
Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Ongoing Investigation Into Potential Securities Law Violations
November 12, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Announces an Investigation of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) on Behalf of Investors
November 12, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox is Investigating Potential Securities Law Violations Against Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
November 11, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations
November 11, 2026
From
Kaplan Fox & Kilsheimer, LLP
Via
GlobeNewswire
MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop
November 11, 2026
From
Kirby McInerney LLP
Via
Business Wire
Kaplan Fox Notifies Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Investigation Into Potential Securities Law Violations
November 10, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
NASDAQ: MDGL Investigation: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
November 10, 2026
RADNOR, PA - November 10, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the...
Via
NewMediaWire
Topics
Whistleblower
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations Investors are Encouraged to Contact the Firm
November 10, 2026
NEW YORK, NY - November 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:...
Via
NewMediaWire
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
November 09, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations
November 09, 2026
From
Kaplan Fox & Kilsheimer, LLP
Via
GlobeNewswire
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
November 09, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Whistleblower
Madrigal Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Madrigal Pharmaceuticals (MDGL)
November 09, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
November 08, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Kaplan Fox Announces an Investigation Into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
November 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
November 06, 2026
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop
November 06, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 8.1% Share Price Decline
November 06, 2026
From
The Law Offices of Howard G. Smith
Via
Business Wire
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
November 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Possible Securities Law Violations
November 05, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline
November 05, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations
November 05, 2026
From
Kaplan Fox & Kilsheimer, LLP
Via
GlobeNewswire
Madrigal (MDGL) Q3 2026 Earnings Call Transcript
↗
November 03, 2026
Rezdiffra hits blockbuster status as net income turns positive for first time.
Via
The Motley Fool
Topics
Earnings
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call
↗
November 03, 2026
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to...
Via
MarketBeat
Topics
Earnings
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
↗
September 10, 2026
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.